36.6 F
New York
Wednesday, January 27, 2021

BioNTech [NASDAQ: BNTX] Expects To File For Regulatory Approval By The End Of 2020

Must read

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

BioNTech SE [NASDAQ: BNTX] disclosed Thursday that it is confident to begin the mass production of vaccine before acquiring the regulatory approval. CEO of BioNtech said that it will be ready to get regulatory approval by the end of the year.

BioNtech CEO and co-founder Dr. Ugur Sahin disclosed that the firm will produce over 1 billion doses by the end of 2021. It has partnered with Pfizer Inc. [NYSE: PFE]. He told the Wall Street Journal that several hundred million doses could be produced even before regulatory approval.

Pfizer and Biotech’s development program consist four vaccine candidates, each representing a different blend of mRNA format and target antigen. The new design of the trial allows for simultaneous review of multiple mRNA candidates in order to identify the safest and possibly most effective candidate for screening as many volunteers as possible. It will be easier to exchange data with regulatory authorities in real time.

Shares of BioNTech SE traded down 2.89% at $65.61 during the last trading session of Thursday. It has a day low and day high range of $64.51-$68.00, respectively. This company’s trading volume is 1.19 million as compared to the average volume of 1.83 million.

From the past 52-weeks of trading, it had fluctuted from the low of $12.52 and a peak of $105.00. Continuing to look at its profitabilty, its gross margin is 88.30% and return on investment is -31.40%.

On the other hand, Pfizer Inc. [NYSE: PFE] shares soared 0.63% at $33.67 during the trading of Friday. Its gross margin is 80.40%, the profit margin is 31.20%, and an operating margin is 32.10%. Its return on assets is 9.60%, return on investment is 14.70%, and return on equity is 25.00%.

More articles

Latest article

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...

Shutterstock [NYSE: SSTK] To Extend Its Agreement With EPA

Shutterstock reported that the company renewed its exclusive contract with the European Pressphoto Agency. The extended contract is to distribute the visual content...